To investigate the suppressive effects of xanthatin on glioma growth in a nude mouse xenograft model and rat orthotopic implantation model using magnetic resonance imaging (MRI) to dynamically monitor the antitumour growth and antiangiogenesis effects of xanthatin. The nude mouse xenograft tumour model and rat orthotopic implantation model were established to observe the antitumour effects of xanthatin in vivo. In the rat orthotopic implanted tumour model, MRI scanning was used to dynamically monitor the antitumour growth effect and evaluate the antiangiogenesis effect of xanthatin. We found that xanthatin at a dose of 0.4 mg/10 g dramatically decreased the growth of xenograft tumours in nude mice. The antiangiogenesis effect of xanthatin C6 glioma was evaluated by dynamic contrast-enhanced (DCE) MRI via comparison of the volume transfer constant (K trans ) value, a parameter that reflects vessel permeability. We found that xanthatin at the doses of 8 and 16 mg/kg significantly decreased the K trans value, which suggests that xanthatin has antiangiogenesis effects. These data demonstrate the suppressive effects of xanthatin on C6 glioma occur via antiangiogenesis. Meanwhile, this study also provides evidence for the application of quantitative parameters of DCE-MRI for dynamically evaluating the growth and angiogenesis of intracranial tumours and for experimental and clinical research.
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antiangiogenesis, glioma, MRI and DCE-MRI, VEGF, xanthatin effect in glioma chemotherapy, its total effectiveness is less than 50% due to drug resistance. It is necessary to find a new agent that can be used alone or in combination withTMZ as an alternative medicine in glioma chemotherapy after surgical resection. Currently, antiangiogenesis therapy is a therapeutic strategy in glioma. Bevacizumab, a recombinant humanized monoclonal antibody, as the first angiogenesis inhibitor, had been approved by the U.S. Food and Drug Administration for use in glioma treatment in clinics. Bevacizumab improves progression-free survival, maintenance of the baseline quality of life, and performance status for patients with newly diagnosed glioblastoma if combined with standard treatment (Chinot et al., 2014) .
Traditional Chinese Medicine (TCM), which is the synthesis of civilization and the wisdom of the Chinese nation, has been used in the treatment of cancer from ancient times until today. TCM plays a specific role in preventing tumour formation, recurrence, and metastasis, as well as in reducing the side effects of tumour therapy. In the treatment of cancer, TCM exhibits unique advantages through multichannel and multitarget effects and leads to less adverse reactions and good tolerance (Qi et al., 2015) . However, due to the complexity of the chemical constituents of
Chinese medicine, it is difficult to justify the clinical outcome and it is difficult to determine the active ingredients and interactions among the ingredients. Xanthium strumarium L., as a traditional Chinese herbal medicine, has been used to treat bacterial infections, diabetes, skin itch, and inflammatory diseases, such as rhinitis and rheumatoid arthritis.
Xanthatin, one of the major active compounds of X. strumarium L., has been reported to inhibit the proliferation of tumour cells, such as A549 nonsmall cell lung cancer cells, H1299 non-small cell lung cancer cells, B16-F10 murine melanoma cells, human breast cancer MDA-MB-231 cells, HL-60 cells, the human leukaemic mast cell line LAD2, and Chinese hamster ovary cells Sanchez-Lamar et al., 2016; Takeda, Noguchi, et al., 2013; Tao et al., 2017; Tao et al., 2013; Tao et al., 2016; Vera et al., 2012; Yu et al., 2015; L. Zhang, Ruan, et al., 2012 (Xuesong et al., 2017) . A combination of a conventional chemotherapy drug (TMZ) and antiangiogenesis drug (bevacizumab) in the C6 glioma model also led to some differences in some quantitative parameters on DCE-MRI (Boult, Terkelsen, Walker-Samuel, Bradley, & Robinson, 2013) . The study by Yu et al. indicated that xanthatin suppressed breast cancer cells proliferation via inhibiting angiogenesis (Yu et al., 2015) . In this article, DCE-MRI was used to investigate whether xanthatin inhibited C6 glioma via antiangiogenesis in a rat orthotopic model of C6 glioma.
Vascular endothelial growth factor (VEGF) acts in a paracrine manner to promote endothelial cell proliferation, survival, and migration in glioma (Plate, Breier, Weich, & Risau, 1992; Saleh, Vasilopoulos, Stylli, Kaye, & Wilks, 1996) . Therefore, VEGF and VEGF receptor have become crucial targets for anticancer therapy.
Bevacizumab has been used to treat glioma in clinics because it selectively binds to VEGF and neutralizes the activity of VEGF. Pluronic F-68), facilitated by ultrasonication, and filtered through a 0.22-μm filter (Merck Millipore, USA) (Tao et al., 2016) . Xanthatin was intraperitoneally injected for 2 weeks, and TMZ was intraperitoneally injected for 1 week. The tumours were measured by Vernier calipers (Meinaite tools, Shanghai, China), and mice were weighed every 2 days.
The tumour volume was calculated by the following equation:
where L is the length and W is the width of the tumour. Then, mice were euthanized with CO 2 , and the tumours were isolated, photographed, and weighed before being fixed with 4% paraformaldehyde. Tissues were cut into 3-μm thick sections after paraffin embedding, and the sections were used for haematoxylin/eosin (HE) staining and immunochemical assays.
| Rat orthotopic implanted tumour model
SD rats were anaesthetized with 10% chloral hydrate (0.3 ml/100 g) by intraperitoneal injection. The head of each rat was immobilized in digital dual lab standard stereotaxic (Stoelting Co., IL, USA) after shearing the fur on the head of the rat. The skin was disinfected with povidone iodine twice before surgery, and sterile drapes were used to cover the rat's head. The skin was cut, and the head was adjusted to ensure that the anterior fontanelle and andalusite occipital fontanelle of the rat were in the same plane. Ten microlitres of the cell suspension (1 × 10 8 cells/ml) was injected into the right caudate putamen using a 25-μl microsyringe at coordinates of 1 mm from the anterior arcuate suture, 3 mm to the right of the sagittalis suture, and 5-mm deep at a rate of 1 μl/min after the skull was drilled at 1 mm. The needle was kept in place for 10 min after the injection. The hole in the skull was sealed with bone wax per day, n = 5 in each group). For xanthatin treatment, rats were injected by the tail vein for 14 days. The weight of the rats was recorded every 2 days. Fourteen days after treatment, rats were euthanized, and their brain and organs were isolated. After being fixed with 4% paraformaldehyde, the tissues were embedded in paraffin and serially cut for histological examination.
| MRI scanning
Rats were scanned with a general electric discovery MR750w 3.0T
MRI scanner (GE, Milwaukee, WI, USA) using a 4-channel animal coil (inner diameter = 5 cm). Rats were anaesthetized with 10% chloral hydrate (0.3 ml/100 g) before scanning. All rats were scanned in the prone position, foot first. The scanning parameters were as follows:
axial 3/6/9/12). Gadodiamide (GE Healthcare, AS, USA) dissolved in 0.6-to 0.8-ml normal saline (total volume 1 ml) was injected into the rat's abdominal cavity at a dose of 0.1-mmol/kg body weight. Thirty minutes after the injection, conventional contrast-enhanced MRI was scanned by a T1-weighted flair sequence. The volume of the tumour was calculated with the following equation:
L, W, and H are the maximum anteroposterior diameter, which measured the largest enhanced areas on the horizontal and coronal planes (X. Zhang, Guo, Shen, & Hu, 2014) . DCE-MRI was performed before and 14 days after rats were treated. DCE-MRI was acquired for seven phases using gadodiamide (Gd) at a dose of 0.3-mmol/kg body weight, and gadodiamide hydrate was dissolved in 0.6-to 0.8-ml normal saline (total volume of 1 ml) and injected via the tail vein. All images were transferred to an independent workstation for quantitative analysis by a noncommercial software (OmniKinetics, GE Healthcare, China). The quantitative parameters were expressed as the mean of five regions of interest in the glioma.
| HE staining and immunohistochemical assay
Glioma tissues were sliced into 3-μm sections, and some sections were stained with HE. The serial C6 glioma sections were incubated with goat serum after deparaffinization and antigen retrieval. Then, the sections were incubated with primary antibodies overnight at 4°C and stained with 3,3′-diaminobenzidine (DAB) tetrahydrochloride.
The nuclei were counterstained with haematoxylin. The glioma slices were observed under a microscope, and the images were collected.
| Statistical analysis
All data are expressed as the mean ± standard deviation (SD).
Statistical comparisons were analysed by one-way analysis of variance with Dunnett's test. p < 0.05 was considered as statistical significance.
3 | RESULTS
| Xanthatin reduces tumour growth in a glioma xenograft model in nude mice
To test whether xanthatin has a therapeutic effect in glioma, a xenograft tumour model in nude mice was developed using C6 cells.
We found that xanthatin obviously reduced the size and weight of tumours isolated from mice treated with xanthatin at a dose of 0.4 mg/10 g compared with those of tumours from the vehicle control (Figure 1a,b) . The tumour size in mice treated with 0.2 mg/10 g xanthatin was close to that of mice in the TMZ group. As shown in Figure 1c , there was no significant difference in the tumour volume between the groups 1-5 days after treatment, but the tumour volume was significantly inhibited 7-15 days after treatment with 0.4-mg/10-g xanthatin, compared with that of the control group.
The tumour volume in the xanthatin middle group (0.2 mg/10 g) was smaller than that in the control group 9-15 days after treatment. These findings suggest that xanthatin inhibited xenograft glioma growth in nude mice. In Figure 1d , the body weight of mice was similar in every group, which suggested that xanthatin has no toxicity.
3.2 | Antitumour effect of xanthatin in a rat orthotopic implanted glioma model on MRI
We established an orthotopic implanted glioma model in rats, and tumour growth was dynamically evaluated by MRI (including T1-weighted imaging (T1WI), T2WI, and Gd-enhanced T1WI). After C6 glioma cells were transplanted, rats were scanned every 2 days to monitor the tumours. After tumours appeared, rats were injected with drugs through the tail vein and scanned by 3.0-T MR every 3 days to dynamically detect the tumour size. We found that tumours were detectable by Gd-enhanced scanning on the seventh day after tumour transplantation ( Figure 2c ). The lesions were located in the right caudate putamen and appeared as a high signal intensity on T2WI
( Figure 2b ). The tumours were smaller in groups treated with xanthatin (8 and 16 mg/kg) than those in the control group (Figure 2c,d ). On T1WI, the signal change of the tumours was not easily observed on 
| DCE-MRI evaluates the effect of xanthatin on vascular permeability
Previous studies have shown that xanthatin inhibits VEGF-induced angiogenesis in breast cancer cells (Yu et al., 2015) . Therefore, we scanned rats by DCE-MRI and acquired some quantitative parameters (K trans , V e , V p , and K ep ) in the regions of interest. As shown in Figure 3a , the signal intensity of gliomas in the xanthatin groups was lower than that of gliomas in the control group. The K trans value in the xanthatin high dose group (16 mg/kg) was significantly different than that in the control group ( Figure 3b ). As shown in Table 1 , the other quantitative parameters (K ep , V e , and V p ) were reduced in the xanthatin groups, but there were no significant differences.
| Correlative study on MRI features and pathology
Tumour tissues were collected on Day 14 after treatment. HE staining was used to observe the morphology and size of the tumours, which were compared with the MRI features. As shown in Figure 4 , the morphology of tumours as determined by MRI (Figure 4a ) and HE staining (Figure 4b ) was consistent. The area in the largest diameter was reduced in the xanthatin groups compared with that in the control group (Figure 4b) . At high magnification, the typical structure of glioma that had crowed nuclei with hyperchromatism and pleomorphism and the necrosis area were seen clearly in the glioma tissues (Figure 4c,d ).
This result suggests that MRI features may objectively reflect the characteristics of glioma.
| Xanthatin downregulates the expression of VEGF in C6 glioma
Because VEGF plays an important role in tumour angiogenesis, we Sanchez-Lamar et al., 2016; Takeda, Noguchi, et al., 2013; Tao et al., 2017; Tao et al., 2013; Tao et al., 2016; Vera et al., 2012; Yu et al., 2015; L. Zhang, Ruan, et al., 2012) . Here, we found that xanthatin significantly inhibited tumour growth in both nude mouse xenograft glioma and rat orthotopic implanted glioma in a dose-dependent manner. The efficiency of xanthatin was better than that of TMZ, the positive control drug. Previous studies showed that the doses of TMZ in rat C6-implanted glioma were much higher than the dose used in our study (Berenguer-Daize et al., 2016; H. Wang et al., 2016) . The dose of TMZ used in this study was based on the normal standard dose used in clinical practice. With this dosage of TMZ, the tumour volume in TMZ-treated rats was significantly less than that in control group rats.
We also found that xanthatin did not affect the body weight of nude mice, which was consistent with the findings reported by Yu et al. (Yu et al., 2015) . The body weight changes in nude mice and rats provided evidence that xanthatin had nearly no toxicity in mice and rats.
The C6 glioma cell line was originally isolated from brain tumours in randomly bred Wistar Furth rats. This cell line was considered to be a useful cell model for the study of glioblastoma growth, for the screening of drug targets, and for the development of novel therapies (San-Galli, Vrignaud, Robert, Coindre, & Cohadon, 1989) . Our group has successfully established a rat orthotopic implantation C6 glioma model (L. Wang et al., 2014) . This study showed that xanthatin inhibited C6 glioma growth in nude mice. To confirm this result, we established a rat orthotopic glioma model. We also determined the antitumour effect of xanthatin in the rat orthotopic glioma model.
These results have not been reported previously. Previous studies mainly focused on the effects of xanthatin on cell lines and nude mice using tumorigenicity assays. Noninvasive MRI was used to dynamically Our study has demonstrated that xanthatin has an antitumour effect in a rat orthotopic glioma model. The next question is how xanthatin crosses the blood-brain barrier (BBB). According to previous studies, we assume that there may be two ways in which xanthatin crosses the BBB: One is that the BBB is damaged during the process of tumour growth, which allows drugs to cross the BBB; the other is that xanthatin can cross the BBB because its structure makes it soluble in fat. In our opinion, the first reason is more likely. According to the directions of the Omniscan (GE Healthcare Ireland), gadodiamide is a nonionic MRI contrast agent and cannot cross the BBB. As shown in Figure 2c , a glioma is clearly observed in the right caudate nucleus in a Gd-enhanced T1WI. This result suggested that the gadodiamide reached the glioma because the BBB was damaged. However, regarding the reasons for how drugs cross the BBB, though it may be true, "BBB leaks" are not a very appealing mechanism of drug delivery because these leaks are limited by blood vessel formation, leakage, and repair. Although this explanation is probably the best solution and interpretation at this moment, it is worth further investigating a better method of drug delivery.
DCE-MRI can be used to study BBB disruptions in vivo. A subtle increasing permeability of the BBB can be detectable in MRI, particularly in patients already exhibiting a cerebrovascular pathology (Heye, Culling, Valdes Hernandez Mdel, Thrippleton, & Wardlaw, 2014; van de Haar et al., 2015) . DCE-MRI has been widely used for early diagnosis, grading and evaluating therapeutic efficacy in clinics (Awasthi et al., 2012; J. Zhang et al., 2017) . DCE-MRI allows contrast agents to be visualized in any given structure over time, so blood flow, blood volume, and permeability can be assessed, thereby demonstrat- was reported that DCE-MRI could be used to evaluate neovascularization patterns in a glioma model (Xuesong et al., 2017) . K trans is defined as the influx volume transfer constant from a blood vessel to extravascular extracellular space. K trans is affected by vascular permeability, blood perfusion, and vascular surface area. K trans has been used as one of the main indicators for the diagnosis, grade, and evaluation of antitumour drugs in glioma (Checkley et al., 2003; Piludu et al., 2015; Sweis et al., 2017; Xue et al., 2017) . K trans was strongly correlated with glioma vascular permeability and microvessel density after antiangiogenesis therapy. In this study, we found that the K trans value in the xanthatin high dose group was lower than that in the control group, suggesting that xanthatin may affect neovascularization in glioma. Some previous studies demonstrated that K trans holds great potential as an imaging biomarker for indicating the variation in sprouting angiogenesis during drug treatment of glioma (Hoff et al., 2012; Xue et al., 2017) . K ep is defined as the microvascular permeability reflux constant. K ep is the rate constant by which a contrast agent in extravascular extracellular space re-enters a blood vessel. K ep reflects the microvessel density, vascular permeability, and vascular osmotic pressure. V e is defined as extravascular extracellular volume.
V e is the percentage of the concentration of the contrast agent in the extravascular extracellular space in the whole body element. V e is related to how much of the contrast agent permeates from the microvessel to the extravascular extracellular space. V e mainly reflects the microvascular permeability of the tissue. V p is defined as fractional plasma volume. V p is the percentage of the concentration of the contrast agent in plasma in the whole body element. V p is related to how much of the contrast agent permeates from the extravascular extracellular space to the microvessel. V p also reflects the microvascular permeability of tissue .
Some studies showed that K ep reflected the microvessel density, vascular permeability, and vascular osmotic pressure and that V e and V p mainly reflected the microvascular permeability of the tissue. Furthermore, these quantitative parameters can reflect angiogenesis in glioma (Sung et al., 2016; Zhang et al., 2017; .
In our research, we also found that although these quantitative parameters were not significantly different among groups, the reduction of some of the quantitative parameters reflected that xanthatin inhibited angiogenesis in glioma. In T2WI, we found that xanthatin reduced the peritumoral oedema area, suggesting that xanthatin may affect angiogenesis in glioma. Therefore, we conclude that xanthatin inhibits C6 glioma via antiangiogenesis effects.
Tumour growth is dependent upon angiogenesis. New blood vessels develop to provide a nutritive supply (Folkman, 1992) . Angiogenesis is required for invasive tumour growth and metastasis. Inhibition of angiogenesis is considered to be a promising approach for antitumor therapy. Angiogenesis is influenced by multiple angiogenic cytokines; VEGF is the most important one among them (Plate et al., 1992; Shweiki, Neeman, Itin, & Keshet, 1995) . VEGF and its receptor 2 are the generally accepted key factors for the formation of blood vessels (Gerber et al., 1998; Koolwijk et al., 2001 ). Bevacizumab, a humanized monoclonal antibody against VEGF, inhibits neovascularization by competitively binding to VEGF and blocking its biological activity. Bevacizumab has been proved to be beneficial for the patients with glioma when combined with fluorouracil-based chemotherapy (Chinot et al., 2014) . VEGF also enhances the permeability of the endothelium and increases vasodilatation through VEGF receptor activation (Bates, Lodwick, & Williams, 1999) . In this study, we found that xanthatin inhibited vascular permeability on the basis of the K trans of MRI. Meanwhile, xanthatin suppressed the expression of VEGF in glioma tissues. These results suggest that xanthatin inhibits angiogenesis, which may because it inhibits the expression VEGF, which is consistent with previous research that found that xanthatin inhibits angiogenesis in breast cancer (Yu et al., 2015) .
Taken together, our data demonstrate the suppressive effects of xanthatin on C6 glioma via antiangiogenesis. Meanwhile, this study also provides evidence for the application of conventional MRI and quantitative parameters of DCE-MRI for dynamically evaluating the
